• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by Surrozen Inc.

    4/23/26 4:59:35 PM ET
    $SRZN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $SRZN alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    Surrozen, Inc./DE

    (Name of Issuer)


    Common Stock, par value $0.0001 per share

    (Title of Class of Securities)




    86889P208

    (CUSIP Number)
    04/22/2026

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)




    schemaVersion:


    SCHEDULE 13G

    CUSIP Number(s):
    86889P208


    1Names of Reporting Persons

    Point72 Asset Management, L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    615,957.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    615,957.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    615,957.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.4 %
    12Type of Reporting Person (See Instructions)

    PN


    SCHEDULE 13G

    CUSIP Number(s):
    86889P208


    1Names of Reporting Persons

    Point72 Capital Advisors, Inc.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    615,957.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    615,957.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    615,957.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.4 %
    12Type of Reporting Person (See Instructions)

    CO


    SCHEDULE 13G

    CUSIP Number(s):
    86889P208


    1Names of Reporting Persons

    Steven A. Cohen
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    615,957.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    615,957.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    615,957.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.4 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Surrozen, Inc./DE
    (b)Address of issuer's principal executive offices:

    171 Oyster Point Blvd, Suite 400, South San Francisco, CA 94080
    Item 2. 
    (a)Name of person filing:

    This statement is filed by: (i) Point72 Asset Management, L.P. ("Point72 Asset Management") with respect to the shares of common stock, par value $0.0001 per share ("Common Stock"), of Surrozen, Inc. held by Point72 Associates, LLC, an investment fund it manages ("Point72 Associates"); (ii) Point72 Capital Advisors, Inc. ("Point72 Capital Advisors Inc.") with respect to the shares of Common Stock held by Point72 Associates; and (iii) Steven A. Cohen ("Mr. Cohen") with respect to the shares of Common Stock beneficially owned by Point72 Asset Management and Point72 Capital Advisors Inc. Point72 Asset Management, Point72 Capital Advisors Inc., and Mr. Cohen have entered into a Joint Filing Agreement, a copy of which is filed with this Schedule 13G as Exhibit 99.1, pursuant to which they have agreed to file this Schedule 13G jointly in accordance with the provisions of Rule 13d-1(k) of the Securities Exchange Act of 1934 (the "Act").
    (b)Address or principal business office or, if none, residence:

    The address of the principal business office of Point72 Asset Management, Point72 Capital Advisors Inc., and Mr. Cohen is 72 Cummings Point Road, Stamford, CT 06902.
    (c)Citizenship:

    Point72 Asset Management is a Delaware limited partnership. Point72 Capital Advisors Inc. is a Delaware corporation. Mr. Cohen is a United States citizen.
    (d)Title of class of securities:

    Common Stock, par value $0.0001 per share
    (e)CUSIP Number(s):

    86889P208
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    The information required by Item 4(a) is set forth in Row 9 of the cover page for each of the Reporting Persons and is incorporated herein by reference. Such information is as of the close of business on April 22, 2026. Point72 Asset Management, Point72 Capital Advisors Inc., and Mr. Cohen own directly no shares of Common Stock. Pursuant to an investment management agreement, Point72 Asset Management maintains investment and voting power with respect to the securities held by Point72 Associates. Point72 Capital Advisors Inc. is the general partner of Point72 Asset Management. Mr. Cohen controls each of Point72 Asset Management and Point72 Capital Advisors Inc. The filing of this statement should not be construed as an admission that any of the foregoing persons or any Reporting Person is, for the purposes of Section 13 of the Act, the beneficial owner of the shares of Common Stock reported herein.
    (b)Percent of class:

    5.4%
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    The information required by Item 4(c)(i) is set forth in Row 5 of the cover page for each of the Reporting Persons and is incorporated herein by reference. Such information is as of the close of business on April 22, 2026.

     (ii) Shared power to vote or to direct the vote:

    The information required by Item 4(c)(ii) is set forth in Row 6 of the cover page for each of the Reporting Persons and is incorporated herein by reference. Such information is as of the close of business on April 22, 2026.

     (iii) Sole power to dispose or to direct the disposition of:

    The information required by Item 4(c)(iii) is set forth in Row 7 of the cover page for each of the Reporting Persons and is incorporated herein by reference. Such information is as of the close of business on April 22, 2026.

     (iv) Shared power to dispose or to direct the disposition of:

    The information required by Item 4(c)(iv) is set forth in Row 8 of the cover page for each of the Reporting Persons and is incorporated herein by reference. Such information is as of the close of business on April 22, 2026.

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Not Applicable
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    See Item 2(a). Point72 Associates has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, more than 5 percent of the outstanding Common Stock.
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Point72 Asset Management, L.P.
     
    Signature:/s/ Jason M. Colombo
    Name/Title:Jason M. Colombo, Authorized Person
    Date:04/23/2026
     
    Point72 Capital Advisors, Inc.
     
    Signature:/s/ Jason M. Colombo
    Name/Title:Jason M. Colombo, Authorized Person
    Date:04/23/2026
     
    Steven A. Cohen
     
    Signature:/s/ Jason M. Colombo
    Name/Title:Jason M. Colombo, Authorized Person
    Date:04/23/2026
    Exhibit Information

    Exhibit 99.1: Joint Filing Agreement

    Get the next $SRZN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SRZN

    DatePrice TargetRatingAnalyst
    4/21/2026Buy
    TD Cowen
    2/19/2026$40.00Overweight
    Cantor Fitzgerald
    1/30/2025$32.00Buy
    H.C. Wainwright
    1/3/2025$45.00Neutral → Buy
    Guggenheim
    10/11/2021$11.00Buy
    B of A Securities
    9/15/2021$20.00Buy
    Guggenheim
    9/7/2021$19.00Buy
    Stifel
    More analyst ratings

    $SRZN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Li Yang

    4 - Surrozen, Inc./DE (0001824893) (Issuer)

    4/1/26 5:43:22 PM ET
    $SRZN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Tcg Crossover Gp Ii, Llc

    4 - Surrozen, Inc./DE (0001824893) (Issuer)

    3/25/26 8:02:09 PM ET
    $SRZN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Large owner Tcg Crossover Gp Ii, Llc bought $1,220,362 worth of shares (48,997 units at $24.91) (SEC Form 4)

    4 - Surrozen, Inc./DE (0001824893) (Issuer)

    3/16/26 7:05:51 PM ET
    $SRZN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SRZN
    SEC Filings

    View All

    SEC Form SCHEDULE 13G filed by Surrozen Inc.

    SCHEDULE 13G - Surrozen, Inc./DE (0001824893) (Subject)

    4/23/26 4:59:35 PM ET
    $SRZN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form DEFA14A filed by Surrozen Inc.

    DEFA14A - Surrozen, Inc./DE (0001824893) (Filer)

    4/1/26 4:25:56 PM ET
    $SRZN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form DEF 14A filed by Surrozen Inc.

    DEF 14A - Surrozen, Inc./DE (0001824893) (Filer)

    4/1/26 4:23:39 PM ET
    $SRZN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SRZN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    TD Cowen initiated coverage on Surrozen

    TD Cowen initiated coverage of Surrozen with a rating of Buy

    4/21/26 7:35:41 AM ET
    $SRZN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Cantor Fitzgerald initiated coverage on Surrozen with a new price target

    Cantor Fitzgerald initiated coverage of Surrozen with a rating of Overweight and set a new price target of $40.00

    2/19/26 7:52:22 AM ET
    $SRZN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    H.C. Wainwright initiated coverage on Surrozen with a new price target

    H.C. Wainwright initiated coverage of Surrozen with a rating of Buy and set a new price target of $32.00

    1/30/25 7:17:42 AM ET
    $SRZN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SRZN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Tcg Crossover Gp Ii, Llc bought $1,220,362 worth of shares (48,997 units at $24.91) (SEC Form 4)

    4 - Surrozen, Inc./DE (0001824893) (Issuer)

    3/16/26 7:05:51 PM ET
    $SRZN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Large owner Tcg Crossover Gp Ii, Llc bought $444,844 worth of shares (18,856 units at $23.59) (SEC Form 4)

    4 - Surrozen, Inc./DE (0001824893) (Issuer)

    2/13/26 4:19:53 PM ET
    $SRZN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Large owner Tcg Crossover Gp Ii, Llc bought $202,534 worth of shares (9,357 units at $21.65) (SEC Form 4)

    4 - Surrozen, Inc./DE (0001824893) (Issuer)

    2/3/26 8:03:54 PM ET
    $SRZN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SRZN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Surrozen Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

    Expect to submit an Investigational New Drug application for SZN-8141 to FDA in the second half of 2026 Scheduled to present retinal vascular research on SZN-8141 at the upcoming 2026 ARVO Annual Meeting Received notice of achievement of research milestone by Boehringer Ingelheim for SZN-413, triggering $5 million milestone payment Strengthened key leadership roles in 2025 to support long-term ophthalmology strategy SOUTH SAN FRANCISCO, Calif., March 23, 2026 (GLOBE NEWSWIRE) -- Surrozen, Inc. ("Surrozen" or the "Company") (NASDAQ:SRZN), a biotechnology company pioneering targeted therapeutics to harness the power of Wnt signaling to address the underlying drivers of disease in sight-t

    3/23/26 4:05:00 PM ET
    $SRZN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Surrozen to Present at Upcoming Healthcare Investor Conference

    SOUTH SAN FRANCISCO, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Surrozen, Inc. ("Surrozen" or the "Company") (NASDAQ:SRZN), a biotechnology company pioneering targeted therapeutics to harness the power of Wnt signaling to address the underlying drivers of disease in sight-threatening ophthalmic conditions, today announced that Company management will present at an upcoming healthcare investor conference. TD Cowen 46th Annual Healthcare Conference on Wednesday, March 4, 2026 Fireside Chat at 1:10 PM Eastern Time / 10:10 AM Pacific Time Interested parties may access the live audio webcast for the conference via the Investors section of the Surrozen website at https://investors.surrozen.com

    2/25/26 4:05:00 PM ET
    $SRZN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Surrozen Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    SOUTH SAN FRANCISCO, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Surrozen, Inc. ("Surrozen" or the "Company") (NASDAQ:SRZN), a biotechnology company pioneering targeted therapeutics to harness the power of Wnt signaling to address the underlying drivers of disease in sight-threatening ophthalmic conditions, today announced that on February 17, 2026, Surrozen granted a non-statutory stock option for an aggregate of 3,070 shares of Surrozen common stock to a recently hired non-executive employee as an inducement material to their acceptance of employment with Surrozen. The stock option was granted under Surrozen's 2025 Equity Inducement Plan which provides for the grant of equity awards to ne

    2/23/26 4:30:00 PM ET
    $SRZN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SRZN
    Leadership Updates

    Live Leadership Updates

    View All

    Surrozen Reports Second Quarter 2025 Financial Results and Provides Business Update

    Daniel Chao, M.D., Ph.D., joins Surrozen as Vice President of Clinical Development Surrozen forms Clinical Advisory Board comprised of leading retinal specialists Data Presentations at Association for Research in Vision and Ophthalmology Annual Meeting and Clinical Trials at the Summit SOUTH SAN FRANCISCO, Calif., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Surrozen, Inc. ("Surrozen" or the "Company") (NASDAQ:SRZN), a biotechnology company pioneering targeted therapeutics that selectively modulate the Wnt pathway for tissue repair and regeneration, with a focus on severe eye diseases, today announced financial results for the second quarter ended June 30, 2025, and provided a business update. Bu

    8/8/25 4:05:56 PM ET
    $SRZN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Surrozen Strengthens Board of Directors with the Appointment of Eric Bjerkholt

    SOUTH SAN FRANCISCO, Calif., April 05, 2023 (GLOBE NEWSWIRE) -- Surrozen, Inc. ("Surrozen" or the "Company") (NASDAQ:SRZN), a company pioneering targeted therapeutics that selectively activate the Wnt pathway for tissue repair and regeneration, today announced that Eric Bjerkholt has been appointed to the Board of Directors. Surrozen's Board of Directors now includes nine members with extensive experience across diverse disciplines in biotechnology and pharmaceutical development. Mr. Bjerkholt brings extensive business leadership experience across a broad range of roles and is currently CFO of Chinook Therapeutics. He most recently served as CFO of Aimmune Therapeutics, Inc. overseeing t

    4/5/23 8:30:00 AM ET
    $SRZN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Surrozen Announces Appointment of Liz Nguyen as Vice President and Head of Human Resources

    SOUTH SAN FRANCISCO, Calif., Sept. 23, 2021 (GLOBE NEWSWIRE) -- Surrozen Inc. (NASDAQ:SRZN), a biotechnology company discovering and developing drug candidates to selectively modulate the Wnt pathway, today announced that Elizabeth "Liz" Nguyen has been appointed as Vice President and Head of Human Resources (HR). Ms. Nguyen brings over 20 years of experience in organizational design, talent recruitment, building a performance culture, planning and leadership development. "Liz is joining Surrozen at a time of tremendous growth as we advance our two lead programs into the clinic and continue our momentum and progress on our broad research pipeline," said Craig Parker, President and Chief

    9/23/21 8:30:00 AM ET
    $SRZN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SRZN
    Financials

    Live finance-specific insights

    View All

    Surrozen Provides Fourth Quarter and Full Year 2022 Financial Results and Update on Clinical Pipeline and Corporate Progress

    Enrolled first patient in SZN-043 Ph 1a clinical trial in chronic liver disease with data expected by the end of 2023 Expect to begin SZN-043 Ph1b clinical trial in severe alcoholic hepatitis in 2024 with proof-of-concept data expected in the second half of 2024 Expect to reinitiate SZN-1326 Ph1a clinical trial in healthy volunteers by mid-2023 with data expected by the end of 2023 Anticipate potential proof-of-concept data for SZN-1326 in ulcerative colitis in the second half of 2024 Expect to nominate a fourth product candidate by the end of 2023 Corporate prioritization and restructuring result in cash runway into the second half of 2024 SOUTH SAN FRANCISCO, Calif., March 22, 2023

    3/22/23 4:01:00 PM ET
    $SRZN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Surrozen To Report Fourth Quarter and Full Year 2022 Financial Results and Provide a Corporate Update on March 22, 2023

    SOUTH SAN FRANCISCO, Calif., March 20, 2023 (GLOBE NEWSWIRE) -- Surrozen, Inc. ("Surrozen" or the "Company") (NASDAQ:SRZN), today announced that it will report fourth quarter and full year 2022 financial results and provide a corporate and pipeline progress report on Wednesday, March 22, 2023 after the close of the U.S. financial markets.   Company management will host a live audio webcast at 4:30 PM Eastern Time to discuss the corporate update and pipeline progress. Interested parties may join the audio webcast via the Investor website at www.surrozen.com. To ensure a timely connection, it is recommended that individuals register at least 15 minutes prior to the start of the webcast. Ab

    3/20/23 4:30:00 PM ET
    $SRZN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SRZN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Surrozen Inc.

    SC 13G/A - Surrozen, Inc./DE (0001824893) (Subject)

    11/14/24 4:34:39 PM ET
    $SRZN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Surrozen Inc.

    SC 13G/A - Surrozen, Inc./DE (0001824893) (Subject)

    11/13/24 5:42:02 PM ET
    $SRZN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Surrozen Inc.

    SC 13G/A - Surrozen, Inc./DE (0001824893) (Subject)

    11/8/24 11:26:54 AM ET
    $SRZN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care